BioCentury
ARTICLE | Clinical News

MiNA reports preliminary Phase I data for liver cancer candidate

May 25, 2018 5:02 PM UTC

MiNA Therapeutics Ltd. (London, U.K.) reported preliminary data from 10 evaluable patients with advanced hepatocellular carcinoma (HCC) in the Phase I OUTREACH trial showing that once-weekly IV MTL-CEBPA led to one partial response with a 73% reduction in tumor volume, plus four cases of stable disease lasting ≥4 months. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

MTL-CEBPA was well tolerated. The maximum tolerated dose (MTD) has not yet been reached in the open-label, dose-escalation, international trial, which is enrolling about 51 patients...